Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.New York's JDS Pharmaceuticals and the North Carolina-based arm of Synthon Pharmaceuticals have entered into a co-promotion agreement for Lithobid, a leading brand of twice-daily lithium carbonate for the treatment of bipolar disorder.
Subscribe to our email newsletter
Synthon will co-promote Lithobid through its sales force of approximately 50 sales representatives to high volume prescribing psychiatrists across the US. Financial terms of the agreement were not disclosed.
“We are enthusiastic about our agreement with Synthon, as it provides significant benefit for both companies,” said Phillip Satow, chairman and CEO of JDS. “For JDS, it is a milestone as we establish ourselves for both near and long-term growth in revenue.”
Andrew Shales, vice president of sales and marketing for Synthon said, “We are very excited about the addition of Lithobid to our portfolio, as it represents an excellent strategic fit for us. It is a very significant addition to our specialty branded business and will further strengthen our US market presence.”